Targets › ALPK1
2 programs from 2 companies in 3 trials: 3 Phase 1; Ophthalmology, Other, Oncology; next expected readout Nov 2026.
Serine/threonine-protein kinase that detects bacterial pathogen-associated molecular pattern metabolites (PAMPs) and initiates an innate immune response, a critical step for pathogen elimination and engagement of adaptive immunity. Specifically recognizes and binds ADP-D-glycero-beta-D-manno-heptose (ADP-Heptose), a potent PAMP present in all Gram-negative and some Gram-positive bacteria. (UniProt, Q96QP1)
Open in Phaseline: the race on ALPK1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm) | DF-003 ALPK1 inhibitor | ALPK1 | Phase 1 | Healthy; ROSAH | Nov 2026 |
| Pyrotech Therapeutics | PTT-936 Alpha Kinase 1 (ALPK1) activator | ALPK1 | Phase 1 | Locally Advanced or Metastatic Solid Tumors | Sep 2027 |
Healthy (1) ROSAH (1) Locally Advanced or Metastatic Solid Tumors (1)
small molecule (2)
Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm) (1) Pyrotech Therapeutics (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.